DLA Piper-Led Gene Therapy Co. Scores $100M In Funding
Locanabio — a DLA Piper-guided company creating gene therapies targeting severe neurodegenerative, neuromuscular and retinal diseases — said Monday that it landed $100 million in a Vida Ventures-led funding round to...To view the full article, register now.
Already a subscriber? Click here to view full article